Vancomycin Prophylaxis for Prevention of <i>Clostridium difficile</i> Infection Recurrence in Renal Transplant Patients

Abstract

Although sufficient power was not obtained to detect statistically significant differences between the intervention and control groups, a 0% incidence of recurrent CDI while receiving VPPx in this high-risk patient population is compelling because it pertains to the avoidance of CDI-related morbidity and mortality in transplant recipients. Future prospective studies are needed to better evaluate the impact of this preventive strategy.